Patient outcomes
UPN . | Age at DLI, y . | Diagnosis . | Time from BMT to relapse, mo . | Time from relapse to DLI, wk . | DLI dose, MNCs × 108/kg . | aDLI dose, CD3+ cells × 106/kg . | Maximal grade of aGVHD . | Maximal response and duration . | Current status . | Time from DLI to last follow-up, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 4799-03 | 54 | CLL | 45 | 6 | 3.5 | 1.0 | II | CR, 53+ mo | Alive in CR | 53+ |
| 649-02 | 19 | ALL | 2 | 3 | 1.0 | 1.0 | NE | NE | Died, disease | 0.8 |
| 4799-05 | 57 | AML | 90 | 2 | 1.5 | 1.0 | I | CR, 40 mo | Relapse after CR, alive with disease | 49+ |
| 649-03 | 16 | ALL (Ph+) | 24 | 24 | 1.0 | 1.0 | 0 | NR | Died, disease | 2.6 |
| 4799-07 | 44 | ALL | 5 | 5 | 0.9 | 3.0 | II | CR, 7 mo | Relapse after CR, died, disease | 8.2 |
| 4799-08 | 52 | NHL | 20 | 6 | 1.0 | 3.0 | 0 | CR, 35+ mo | Alive in CR | 35+ |
| 4799-11 | 45 | Myeloma | 5 | 5 | 1.6 | 3.0 | I | NR | Died, disease | 13.8 |
| 4799-09 | 53 | AML | 2 | 3 | 2.4 | 10.0 | III | PR, 6 mo | Died, disease | 6.7 |
| 4799-13 | 32 | ALL | 10 | 9 | 1.5 | 10 | 0 | CR, 22 mo | Relapse after CR, alive with disease | 24+ |
| 4799-14 | 28 | LL | 3 | 2 | 1.8 | 10 | III | NR | Died, disease | 3.0 |
| 4799-15 | 36 | CML-BC | 13 | 2 | 1.6 | 10 | 0 | NR | Died, disease | 3.6 |
| 649-04 | 12 | ALL (Ph+) | 8 | 6 | 1.1 | 30 | 0 | CR, 16 mo | Relapse after CR, alive with disease | 16+ |
| 4799-16 | 54 | HD | 38 | 6 | 1.5 | 30 | 0 | NR | Alive with disease | 11+ |
| 4799-18 | 49 | NHL | 29 | 9 | 1.5 | 30 | 0 | NR | Alive with disease | 13+ |
| 4799-20 | 36 | AML | 83 | 8 | 1.0 | 30 | 0 | NR | Died, disease | 4 |
| 4799-21 | 43 | ALL | 4 | 31 | 1.3 | 100 | 0 | SD, 13 mo | Alive with disease | 13+ |
| 4799-23 | 46 | ALL | 19 | 10 | 2.0 | 100 | 0 | CR, 11+ mo | Alive in CR (PCR-) | 11+ |
| 4799-24 | 46 | APML | 5 | 3 | 2.2 | 100 | I | CR, 12+ mo | Alive in CR (PCR-) | 12+ |
UPN . | Age at DLI, y . | Diagnosis . | Time from BMT to relapse, mo . | Time from relapse to DLI, wk . | DLI dose, MNCs × 108/kg . | aDLI dose, CD3+ cells × 106/kg . | Maximal grade of aGVHD . | Maximal response and duration . | Current status . | Time from DLI to last follow-up, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 4799-03 | 54 | CLL | 45 | 6 | 3.5 | 1.0 | II | CR, 53+ mo | Alive in CR | 53+ |
| 649-02 | 19 | ALL | 2 | 3 | 1.0 | 1.0 | NE | NE | Died, disease | 0.8 |
| 4799-05 | 57 | AML | 90 | 2 | 1.5 | 1.0 | I | CR, 40 mo | Relapse after CR, alive with disease | 49+ |
| 649-03 | 16 | ALL (Ph+) | 24 | 24 | 1.0 | 1.0 | 0 | NR | Died, disease | 2.6 |
| 4799-07 | 44 | ALL | 5 | 5 | 0.9 | 3.0 | II | CR, 7 mo | Relapse after CR, died, disease | 8.2 |
| 4799-08 | 52 | NHL | 20 | 6 | 1.0 | 3.0 | 0 | CR, 35+ mo | Alive in CR | 35+ |
| 4799-11 | 45 | Myeloma | 5 | 5 | 1.6 | 3.0 | I | NR | Died, disease | 13.8 |
| 4799-09 | 53 | AML | 2 | 3 | 2.4 | 10.0 | III | PR, 6 mo | Died, disease | 6.7 |
| 4799-13 | 32 | ALL | 10 | 9 | 1.5 | 10 | 0 | CR, 22 mo | Relapse after CR, alive with disease | 24+ |
| 4799-14 | 28 | LL | 3 | 2 | 1.8 | 10 | III | NR | Died, disease | 3.0 |
| 4799-15 | 36 | CML-BC | 13 | 2 | 1.6 | 10 | 0 | NR | Died, disease | 3.6 |
| 649-04 | 12 | ALL (Ph+) | 8 | 6 | 1.1 | 30 | 0 | CR, 16 mo | Relapse after CR, alive with disease | 16+ |
| 4799-16 | 54 | HD | 38 | 6 | 1.5 | 30 | 0 | NR | Alive with disease | 11+ |
| 4799-18 | 49 | NHL | 29 | 9 | 1.5 | 30 | 0 | NR | Alive with disease | 13+ |
| 4799-20 | 36 | AML | 83 | 8 | 1.0 | 30 | 0 | NR | Died, disease | 4 |
| 4799-21 | 43 | ALL | 4 | 31 | 1.3 | 100 | 0 | SD, 13 mo | Alive with disease | 13+ |
| 4799-23 | 46 | ALL | 19 | 10 | 2.0 | 100 | 0 | CR, 11+ mo | Alive in CR (PCR-) | 11+ |
| 4799-24 | 46 | APML | 5 | 3 | 2.2 | 100 | I | CR, 12+ mo | Alive in CR (PCR-) | 12+ |
UPN indicates unique patient number; MNCs, mononuclear cells; aGVHD, acute GVHD; CR, complete remission; NE, not evaluable; NR, no response; PR, partial response; LL, lymphoblastic lymphoma; CML-BC, chronic myelogenous leukemia-blast crisis; HD, Hodgkin disease; SD, stable disease; APML, acute promyelocytic leukemia; and PCR, polymerase chain reaction.